Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Free Cash Flow (2016 - 2025)

Mimedx's Free Cash Flow history spans 15 years, with the latest figure at $24.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 33.22% year-over-year to $24.7 million; the TTM value through Dec 2025 reached $73.5 million, up 11.8%, while the annual FY2025 figure was $73.0 million, 13.11% up from the prior year.
  • Free Cash Flow for Q4 2025 was $24.7 million at Mimedx, down from $29.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $29.1 million in Q3 2025 and bottomed at -$10.3 million in Q1 2022.
  • The 5-year median for Free Cash Flow is $6.6 million (2021), against an average of $7.6 million.
  • The largest annual shift saw Free Cash Flow tumbled 311.69% in 2022 before it soared 3496.72% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$3.2 million in 2021, then crashed by 94.65% to -$6.3 million in 2022, then surged by 247.35% to $9.3 million in 2023, then surged by 99.77% to $18.5 million in 2024, then surged by 33.22% to $24.7 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Free Cash Flow are $24.7 million (Q4 2025), $29.1 million (Q3 2025), and $14.4 million (Q2 2025).